Cabaletta Bio Inc (NASDAQ: CABA) is a clinical-stage biopharmaceutical company developing chimeric antigen receptor T cell (CART) therapies targeting B cell-driven autoimmune diseases. The company has no product revenue as of December 31, 2025, and funds operations through equity raises, including a June 2025 offering that issued 53,090,190 common stock warrants alongside common stock and pre-funded warrants. Its lead program, rese-cel, is in clinical development across multiple autoimmune indications, supported by manufacturing agreements with Minaris and Lonza Houston Inc. (executed December 2024) and Cellares Corporation (executed January 2026). Cabaletta holds a license from the University of Pennsylvania covering key underlying technology, under which it owes milestone and royalty payments contingent on development, regulatory, and commercial achievements. As of December 31, 2025, no milestone timing or likelihood could be estimated. The company operates with limited resources and has disclosed an explicit strategy of concentrating on a small number of clinical programs, with rese-cel and MuSK-CAART as its primary pipeline assets.

Revenue model

No product revenue as of December 31, 2025. Operations are funded through equity financings. Future revenue, if any, would depend on milestone payments received under licensing arrangements and eventual product sales, with royalty obligations owed to the University of Pennsylvania on any commercialized products.

Products and services

Lead clinical asset: rese-cel (resettable CAR-T cell therapy), in development for multiple autoimmune indications including potential late-stage trials and commercial readiness activities as of the 10-K filed 2026-03-23. Secondary program: MuSK-CAART, targeting MuSK-positive myasthenia gravis. Earlier-stage program: MusCAARTesTM trial referenced in manufacturing agreements.

Customers and end markets

No commercial customers as of December 31, 2025. End market is patients with B cell-mediated autoimmune diseases. Clinical programs are in development phase with no approved products.

Value-chain role

Clinical-stage drug developer. Relies on contract manufacturing organizations (CMOs) including Minaris, Lonza Houston Inc., and Cellares Corporation for cell processing and GMP manufacturing. Relies on contract research organizations (CROs) for clinical operations. Holds an in-licensed technology platform from the University of Pennsylvania.

Geographic exposure

Primarily U.S.-based operations. Manufacturing and clinical development agreements reference global clinical development for rese-cel across multiple indications. University of Pennsylvania license covers milestone payments on a product-by-product and geographical basis.

Source: SEC 10-K, filed 2026-03-23

Industry: Biological Products, (No Diagnostic Substances) Peers: Theriva Biologics Inc Aptevo Therapeutics Inc bioAffinity Technologies Inc Vyant Bio, Inc. Bio Green Med Solution Inc HUMANIGEN, INC YIELD10 BIOSCIENCE, INC. NexImmune, Inc. Sigilon Therapeutics, Inc.